In primary NSCLC cells and established cell lines ASP4132 potently inhibited cell growth, proliferation and cell cycle progression as well as cell migration and invasion.
[Cell Death & Disease]
A dual-luciferase reporter system and RIP assays showed that UCC specifically bound to miR-143-3p and acted as a sponge of miR-143-3p in NSCLC cells.
6445218 LHAUUFEG items 1 apa default asc 1
Sorrento Therapeutics, Inc. announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA Therapeutics, Inc. The acquisition will include late clinical stage drug Abivertinib, clinical stage candidate AC0058, preclinical stage candidate AC0939, and ACEA’s extensive proprietary library of small molecules, which potentially have applications for numerous human disease indications, including non-small cell lung cancer, B cell lymphomas, systemic lupus, rheumatoid arthritis, multiple sclerosis and viral infections.
[Sorrento Therapeutics, Inc. (Globe Newswire, Inc.)]
6445218 nan items 1 apa default asc 1
The authors explore current diagnostic problems of gene fusion detection relative to the technologies available, in order to clarify future standardization of analyses which determine therapeutic choices.
[Expert Review of Anticancer Therapy]
1254621 RF4Q7728 items 1 apa default asc 1
Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Tecentriq® as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.
1254621 nan items 1 apa default asc 1
Functional experiments showed that MCF2L‐AS1 knockdown suppressed the cancer stem cell‐like traits of non-small cell lung cancer cells through qRT‐PCR, western blot, tumor‐sphere formation, and ALDH activity detection.
6445212 63HQKM75 items 1 apa default asc 1
PC9 and HCC827 non‐small cell lung cancer cell lines were treated with high concentrations of gefitinib, and surviving cells were referred to as “gefitinib‐resistant persisters” (GRPs). Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) knockdown or overexpression was performed to determine the biological significance of ZEB1 in the cancer stem cell features of GRPs, and animal models were studied for in vivo validation.
1254621 3LGLVK6Z items 1 apa default asc 1
Nurwidya, F., Takahashi, F., Winardi, W., Tajima, K., Mitsuishi, Y., Murakami, A., Kobayashi, I., Nara, T., Hashimoto, M., Kato, M., Hidayat, M., Suina, K., Hayakawa, D., Asao, T., Ko, R., Shukuya, T., Yae, T., Shimada, N., Yoshioka, Y., … Takahashi, K. (n.d.). Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib. Thoracic Cancer, n/a(n/a). https://doi.org/https://doi.org/10.1111/1759-7714.13937 Cite
Scientists showed that mitotic spindle organizing protein 2A (MZT2A) exhibited oncogenic activity by activating galectin‐3‐binding protein and Akt in NSCLC.
6606345 8HFGRL7Y items 1 apa default asc 1
Wang, H., Jiang, X., Cheng, Y., Ren, H., Hu, Y., Zhang, Y., Su, H., Zou, Z., Wang, Q., Liu, Z., Zhang, J., & Qiu, X. (n.d.). MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain. Cancer Science, n/a(n/a). https://doi.org/https://doi.org/10.1111/cas.14900 Cite
miR‑454‑3p overexpression led to the suppression of proliferation, migration, and invasion in A549 and NCI‑H1650 cells. The overexpression of miR‑454‑3p in A549 and NCI‑H1650 cells significantly inhibited EMT. TGFB2 was revealed to be a direct target of miR‑454‑3p by using TargetScan database and luciferase reporter assay.
Musashi-2 (MSI2) control of epidermal growth factor receptor (EGFR) expression and activity in an NSCLC cell line panel was studied using RT-PCR, Western blots, and RNA immunoprecipitation. Functional consequences of MSI2 depletion were explored for cell growth and response to EGFR-targeting drugs, in vitro and in vivo.
6606345 SWP37FM8 items 1 apa default asc 1
Makhov, P., Bychkov, I., Faezov, B., Deneka, A., Kudinov, A., Nicolas, E., Brebion, R., Avril, E., Cai, K. Q., Kharin, L. V., Voloshin, M., Frantsiyants, E., Karnaukhov, N., Kit, O. I., Topchu, I., Fazliyeva, R., Nikonova, A. S., Serebriiskii, I. G., Borghaei, H., … Boumber, Y. (2021). Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC). Oncogenesis, 10(3), 1–14. https://doi.org/10.1038/s41389-021-00317-y Cite
In this review, scientists discuss some uncommon alterations in NSCLC such as ROS1, BRAF, RET, HER2, NTRK, MET and other targets that are in an early evaluation phase.
[Critical Reviews in Oncology/Hematology]
6606345 RT6N2KMF items 1 apa default asc 1
De Toma, A., Lo Russo, G., Signorelli, D., Pagani, F., Randon, G., Galli, G., Prelaj, A., Ferrara, R., Proto, C., Ganzinelli, M., Zilembo, N., de Braud, F., & Garassino, M. C. (2021). Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Critical Reviews in Oncology/Hematology, 160, 103299. https://doi.org/10.1016/j.critrevonc.2021.103299 Cite